Mode
Text Size
Log in / Sign up
Phase 4 Completed N=70 Randomized Quadruple-blind Treatment

Single-shot TAP Block vs Continuous TAP Block

Source: ClinicalTrials.gov NCT02475031 ↗
Enrolled (actual)
70
Serious AEs
Results posted
May 2017
Primary outcomePrimary: Total Narcotic Usage at 48 Hours — 2.44; 2.88 mg
◆ Published Evidence
Established
28citations · ~5 / year
Transversus abdominis plane (TAP) block for laparoscopic live donor nephrectomy: Continuous catheter infusion provides no additional analgesic benefit over single-injection ropivacaine.
Clinical transplantation · 2020 · High-confidence link

Summary

The purpose of this study is to determine whether continuous transversus abdominis plane (TAP) block is superior to single shot TAP for postoperative pain after laparoscopic donor nephrectomy

Linked Publications

  • Transversus abdominis plane (TAP) block for laparoscopic live donor nephrectomy: Continuous catheter infusion provides no additional analgesic benefit over single-injection ropivacaine.
    Clinical transplantation · 2020 · 28 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Narcotic Usage at 48 Hours
2.44; 2.88
SECONDARY
Secondary Endpoints Measured Will be Total Narcotic Usage at 60 Hours
14.31; 14.40
SECONDARY
Average Pain Scores
5.31; 5.06
SECONDARY
Nausea Scores at 48 Hours
0.34; 0.34
SECONDARY
Sedation Scores at 48 Hours
0.2; 0.06

Eligibility Criteria

Inclusion criteria

  • Healthy subject undergoing laparoscopic live donor nephrectomy
  • (ASA) American Society of Anesthesiologists class 1 or 2
  • Age 18 or older, male or female
  • Desires TAP block for postoperative pain control

Exclusion criteria

  • Any contraindication for TAP block - single or continuous
  • History of substance abuse
  • Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.
  • Known allergy or other contraindications to the study medications (Ropivacaine, Normal Saline, Hydromorphone, Oxycodone and Acetaminophen)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02475031) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search